NDA 021519 · Ani Pharms
Luvox
Fluvoxamine Maleate · Oral
Last checked: Nov 20, 2026Latest source record: Aug 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2007
Dec 20, 2007
Approved uses
1
Original approval plus efficacy supplements
Registered trials
92
15 Phase 3, 8 recruiting
FAERS reports
2,440
1,911 serious, 269 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of Fluvoxamine Maleate Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored...
What it is approved for
From the label in effect Apr 23, 2026.
Fluvoxamine Maleate Tablets are indicated for the treatment of obsessions and compulsions in patients with obsessive compulsive disorder (OCD) ( 1 ). 1.1 Obsessive-Compulsive Disorder Fluvoxamine Maleate Tablets are indicated for the treatment of obsessions and compulsions in patients with obsessive compulsive disorder (OCD), as defined in DSM-III-R or DSM-IV. The obsessions or compulsions cause marked distress, are time-consuming, or significantly interfere with social or occupational functioning. Obsessive compulsive disorder is characterized by recurrent and persistent ideas, thoughts, impulses or images (obsessions) that are ego-dystonic and/or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable. The efficacy of Fluvoxamine Maleate Tablets was established in four trials in outpatients with OCD: two 10-week trials in adults, one 10-week trial in pediatric patients (ages 8-17), and one maintenance trial in adults [see Clinical Studies ( 14 )] .
Mechanism: The mechanism of action of fluvoxamine maleate in obsessive compulsive disorder is presumed to be linked to its specific serotonin reuptake inhibition in brain neurons. Fluvoxamine has been shown to be a potent inhibitor of the serotonin reuptake transporter in preclinical studies, both in vitro and in vivo .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 20, 2007 Original approval · Type 3 - New Dosage Form Other Important Information from FDAReviewSummary Review
3 products under this application
- LUVOX · FLUVOXAMINE MALEATE 100MG · TABLET, ORAL · Prescription · TE AB
- LUVOX · FLUVOXAMINE MALEATE 25MG · TABLET, ORAL · Prescription · TE AB
- LUVOX · FLUVOXAMINE MALEATE 50MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Fluvoxamine" as an intervention, any sponsor and status, largest first.
- ACTIV-6: COVID-19 Study of Repurposed MedicationsPivotal-lookingCompleted
Susanna Naggie, MDAcademic, hospital or other
NCT04885530 · 10,956 participants · Start Jun 8, 2021 · Primary completion Apr 29, 2024
Drug: Ivermectin; Fluvoxamine and 3 more · For: Covid19
Sites: Chandler, Arizona; Gilbert, Arizona; Mesa, Arizona · 110 sites in all
- Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild SymptomsPivotal-lookingStatus unknown
CardresearchAcademic, hospital or other
NCT04727424 · 7,819 participants (planned) · Start Jan 19, 2021 · Primary completion Jun 1, 2024
Drug: Budesonide Powder; Fluoxetine 20 MG and 1 more · For: Covid19; SARS-Associated Coronavirus
Sites: Belo Horizonte, Brazil; Betim, Brazil; Brumadinho, Brazil · 12 sites in all
Peking UniversityAcademic, hospital or other
NCT02023567 · 2,400 participants (planned) · Start Nov 2013 · Primary completion Dec 2016
Drug: SSRIs · For: Depressive Disorder, Major
Sites: Beijing, China; Shijiazhuang, China; Dalian, China · 9 sites in all
- Pragmatic Trial of Obsessive-compulsive DisorderPivotal-lookingRecruiting
Shanghai Mental Health CenterAcademic, hospital or other
NCT04539951 · 1,600 participants (planned) · Start Sep 22, 2020 · Primary completion Jun 30, 2027
Drug: Sertraline 200 milligram(mg); Sertraline 300 milligram(mg) and 4 more · For: Obsessive-Compulsive Disorder
Sites: Shanghai, China
- ACTIV-6: COVID-19 Study of Repurposed Medications - Arm B (Fluvoxamine)Pivotal-lookingCompleted
Susanna Naggie, MDAcademic, hospital or other
NCT05890586 · 1,331 participants · Start Jun 8, 2021 · Primary completion Jul 4, 2022
Drug: Fluvoxamine · For: Covid19
Sites: Gilbert, Arizona; Mesa, Arizona; Peoria, Arizona · 91 sites in all
- COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)Pivotal-lookingCompleted
University of MinnesotaAcademic, hospital or other
NCT04510194 · 1,323 participants · Start Jan 1, 2021 · Primary completion Dec 14, 2022
Drug: Metformin; Placebo and 2 more · For: Covid19; SARS-CoV Infection
Sites: Sylmar, California; Aurora, Colorado; Golden, Colorado · 7 sites in all
- ACTIV-6: COVID-19 Study of Repurposed Medications - Arm E (Fluvoxamine 100)Pivotal-lookingCompleted
Susanna Naggie, MDAcademic, hospital or other
NCT05894564 · 1,208 participants · Start Aug 25, 2022 · Primary completion Feb 27, 2023
Drug: Fluvoxamine · For: Covid19
Sites: Gilbert, Arizona; Mesa, Arizona; Peoria, Arizona · 103 sites in all
- Randomized-controlled Trial of the Effectiveness of COVID-19 Early Treatment in CommunityPivotal-lookingCompleted
Chulalongkorn UniversityAcademic, hospital or other
NCT05087381 · 1,200 participants · Start Oct 1, 2021 · Primary completion Jun 21, 2022
Drug: FluvoxaMINE Maleate 50 MG; Niclosamide Pill · For: Treatment Efficacy
Sites: Ratchathewi, Thailand; Bangkok, Thailand; Chiang Mai, Thailand
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug interaction230
- drug ineffective147
- nausea130
- somnolence115
- anxiety111
- suicidal ideation103
- depression96
- dizziness96
- headache94
- fatigue88
- insomnia88
- condition aggravated85
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 104 |
| 2005 | 92 |
| 2006 | 92 |
| 2007 | 97 |
| 2008 | 153 |
| 2009 | 138 |
| 2010 | 117 |
| 2011 | 93 |
| 2012 | 171 |
| 2013 | 45 |
| 2014 | 44 |
| 2015 | 42 |
| 2016 | 75 |
| 2017 | 61 |
| 2018 | 85 |
| 2019 | 67 |
| 2020 | 84 |
| 2021 | 95 |
| 2022 | 122 |
| 2023 | 123 |
| 2024 | 138 |
| 2025 | 255 |
| 2026 | 147 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.
Cipriani A, Furukawa TA, Salanti G, et al. · Lancet 2018 · Comparative Study, Research Support, Non-U.S. Gov't
- Pharmacological treatments in panic disorder in adults: a network meta-analysis.
Guaiana G, Meader N, Barbui C, et al. · Cochrane Database Syst Rev 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
Kishi T, Ikuta T, Sakuma K, et al. · Mol Psychiatry 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis.
Siafis S, Çray O, Wu H, et al. · Mol Autism 2022 · Network Meta-Analysis, Research Support, Non-U.S. Gov't
- Pharmacotherapies for Adults With Alcohol Use Disorders: A Systematic Review and Network Meta-analysis.
Bahji A, Bach P, Danilewitz M, et al. · J Addict Med 2022 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis.
Cipriani A, Furukawa TA, Salanti G, et al. · Lancet 2009 · Comparative Study, Meta-Analysis
Sponsor: Ani Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.